Overview

Intraoperative Goal-directed Blood Pressure and Dexmedetomidine

Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
0
Participant gender:
All
Summary
Perioperative organ injuriy remain an important threat to patients undergoing major surgeries. Intraoperative hypotension is associated with an increase in postoperative morbidity and mortality. Whereas individualized intraoperative blood pressure management is likely to decrease the incidence of postoperative organ injury when compared with standard blood pressure management strategy. Dexmedetomidine, a highly selective alpha2 adrenergic agonist, has been shown to provide organ protective effects. This study aims to investigate the impact of intraoperative goal-directed blood pressure management and dexmedetomidine infusion on incidence of postoperative organ injury in high-risk patients undergoing major surgery.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking University First Hospital
Treatments:
Anesthetics
Dexmedetomidine
Norepinephrine
Criteria
Inclusion Criteria:

- Age 50 years or older;

- Scheduled to undergo abdominal surgery under general anesthesia with an expected
duration of 2 hours or longer;

- With a preoperative acute kidney injury risk index of class III or higher (meet 4 or
more of the following factors: age ≥56 years, male sex, active congestive heart
failure, ascites, hypertension, emergency surgery, intraperitoneal surgery, mild or
moderate renal insuffificiency, diabetes mellitus requiring oral or insulin therapy).

Exclusion Criteria:

- Severe uncontrolled hypertension (SBP>180 mmHg or diastolic blood pressure >110 mmHg);

- Acute or decompensated heart failure, acute coronary syndrome, or stroke within 1
month;

- Severe bradycardia (heart rate < 50 bpm), sick sinus syndrome, second-degree or higher
atrioventricular block without pacemaker, atrial fibrillation, or frequent premature
beats;

- Severe hepatic dysfunction (Child-Pugh C) or chronic kidney disease (glomerular
filtration rate <30 ml/min/1.73 m2 or dependent on renal replacement therapy) ;

- Pregnant;

- Receiving dexmedetomidine or norepinephrine infusion before surgery;

- Do not provide written informed consent.